Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Urología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
INTERVENTIONAL
Inicio: 27 de jun de 2018
ID: NCT03474107
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
INTERVENTIONAL
Inicio: 9 de jun de 2017
ID: NCT03142334
Completado
Fase 1 temprana
ClinicalTrials.gov
Phase 1 Trial of the Implementation of an Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
INTERVENTIONAL
Inicio: 1 de oct de 2023
ID: NCT06334796
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
INTERVENTIONAL
Inicio: 31 de dic de 2023
ID: NCT06136624
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
INTERVENTIONAL
Inicio: 29 de abr de 2019
ID: NCT03785925
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
INTERVENTIONAL
Inicio: 4 de nov de 2011
ID: NCT01374906
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
INTERVENTIONAL
Inicio: 11 de mar de 2025
ID: NCT06833073
Reclutando
Fase 3
ClinicalTrials.gov
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
INTERVENTIONAL
Inicio: 19 de jul de 2024
ID: NCT06282575
Desconocido
ClinicalTrials.gov
Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases
OBSERVATIONAL
Inicio: 1 de ene de 2016
ID: NCT03210298
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 (Zibotentan) in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-resistant Prostate Cancer
INTERVENTIONAL
Inicio: 1 de ene de 2008
ID: NCT00617669
Por invitación
ClinicalTrials.gov
Phenotypic Manifestations of Hereditary ATTR Amyloidosis Val50Met Variant in a Non-endemic Area. Descriptive Study
OBSERVATIONAL
Inicio: 1 de sept de 2024
ID: NCT07124377
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
INTERVENTIONAL
Inicio: 13 de mar de 2025
ID: NCT06764485
Activo, no recluta
Fase 3
ClinicalTrials.gov
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
INTERVENTIONAL
Inicio: 25 de feb de 2021
ID: NCT04586231
Completado
Fase 3
ClinicalTrials.gov
An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies
INTERVENTIONAL
Inicio: 1 de mar de 2011
ID: NCT01223027
Completado
Fase 3
ClinicalTrials.gov
Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
INTERVENTIONAL
Inicio: 22 de nov de 2011
ID: NCT01419717
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 23 de jul de 2017
ID: NCT03141177
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.
INTERVENTIONAL
Inicio: 13 de jul de 2020
ID: NCT04493853
Completado
Fase 3
ClinicalTrials.gov
A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
INTERVENTIONAL
Inicio: 1 de sept de 2007
ID: NCT00474786
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
INTERVENTIONAL
Inicio: 26 de nov de 2025
ID: NCT07227402
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
INTERVENTIONAL
Inicio: 9 de abr de 2024
ID: NCT06211764
Anterior
1
...
12
13
14
...
434
Siguiente
Filtros